GlassScriptPhysician profile
Cindy Ferguson
NPI 1891548921
$3,714.48
in general payments reported to CMS, 2019-2025
43 companies · $3,558 in 2025
The $3,558 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $157 · 2025: $3,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,401 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.73 |
| Education | $313.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $265.39 | 2025 | Monjuvi, Zynyz, Jakafi |
| Janssen Biotech, INC. | $264.35 | 2025 | Talvey, Carvykti, Rybrevant |
| Astellas Pharma US INC | $258.83 | 2025 | Vyloy |
| Novartis Pharmaceuticals Corporation | $240.51 | 2025 | |
| Daiichi Sankyo INC. | $186.18 | 2025 | Enhertu, Vanflyta, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $176.70 | 2025 | Alunbrig, Fruzaqla, Iclusig |
| Pharmaessentia USA Corporation | $174.43 | 2024-2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $171.32 | 2025 | Imfinzi, Enhertu |
| Geron Corporation | $137.87 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $136.20 | 2025 | Keytruda, Lynparza |
| Pfizer INC. | $128.70 | 2025 | |
| Sobi, INC | $114.41 | 2024-2025 | |
| Celgene Corporation | $99.04 | 2025 | Reblozyl |
| Agios Pharmaceuticals, INC. | $96.13 | 2025 | Pyrukynd |
| Array Biopharma INC | $93.76 | 2025 | Braftovi, Mektovi, Lorbrena |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.